The specter of generic rivalry has repeatedly loomed over copyright’s iconic drug, Viagra, triggering questions about the prospects of similar drug stakes. While early periods saw significant returns, the intellectual property end has opened the door for cheaper substitutes, likely diminishing revenue and posing a real risk for shareholders seeki